Healthcare Business Review: GenVec’s Conference Success, Neurocrine Begins Trials
Shares of biopharmaceutical developer GenVec (NASDAQ:GNVC) pop on positive data in regards to one of its RSV vaccine programs at a conference over the past weekend. The firm reports that data on its vaccine candidate showed it to be highly immunogenic and avoids the problems of vector specific immunity that has troubled other similar vectored vaccines.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Neurocrine Biosciences (NASDAQ:NBIX) reports that it has begun Phase IIb clinical trials of NBI-98854, which is its proprietary Vesicular Mono-Amine Transporter 2 compound for the treatment of severe tardive dyskinesia and underlying schizophrenia or schizoaffective disorder. The second quarter of its fiscal year 2013 should see topline data on the study.
Pfizer, Inc. (NYSE:PFE) and Bristol Myers Squibb Co. (NYSE:BMY) might not hear a decision as to whether their experimental blood thinner Eliquis is approved by the FDA until March 2013. Pfizer shares were still up moderately in late afternoon trading.
Don’t Miss: What’s Next in Pfizer’s Pipeline?